Company Encyclopedia
View More
name
INNOCARE
09969.HK
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a registrational trial for the treatment of solid tumor patients, including cholangiocarcinoma; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase II clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases.
1.377 T
09969.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking16/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-3.41%D
    • Profit Margin-16.09%D
    • Gross Margin87.38%A
  • Growth ScoreB
    • Revenue YoY57.12%A
    • Net Profit YoY39.47%B
    • Total Assets YoY-0.69%D
    • Net Assets YoY-3.46%D
  • Cash ScoreC
    • Cash Flow Margin-621.43%E
    • OCF YoY57.12%A
  • Operating ScoreD
    • Turnover0.15D
  • Debt ScoreB
    • Gearing Ratio29.88%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis

    InnoCare Pharma has dosed the first patient in a global Phase II trial of its TYK2 inhibitor, Soficitinib, for prurigo nodularis. The drug targets T-cell related autoimmune disorders, focusing on dermatological conditions. Previous trials showed efficacy in atopic dermatitis. The prurigo nodularis market is projected to grow from $2 billion in 2024 to $3 billion by 2034. This news was generated by AI and published by InnoCare via GlobeNewswire.

    Reuters·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%
    Reuters·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%

    Shenwan Hongyuan Sticks to Their Buy Rating for InnoCare Pharma Ltd. (9969)

    Shenwan Hongyuan analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$19.00.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$23.20.

    Tip Ranks·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%
    Tip Ranks·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%

    UBS lists predictions for Chinese stocks with high profit growth potential for next year (Table)

    UBS released a strategy report on the Chinese market, listing Chinese stocks with high profit growth potential for next year and giving them a "Buy" rating. The list includes Hong Kong stocks and Chinese concept stocks, such as InnoCare Pharma, Kintor Pharmaceutical, Zai Lab, Akeso, ECARX Holdings, CanSinoBIO, Zhongsheng Holdings, BeiGene, Li Auto, GDS Holdings, and iQIYI

    AASTOCKS·
    US
    ZLAB
    +1.01%
    HK
    09688
    -0.45%
    SH
    688185
    +0.64%
    AASTOCKS·
    US
    ZLAB
    +1.01%
    HK
    09688
    -0.45%
    SH
    688185
    +0.64%

    UBS lowers InnoCare Pharma's target price to 23.6 yuan, last quarter's performance generally in line with expectations

    UBS published a research report stating that InnoCare Pharma's third-quarter performance met expectations, with a revenue growth of 38%, but the net loss was higher than market expectations. Sales of the core product Orelabrutinib were strong, and the company expects sales to grow by more than 35% in 2025. UBS adjusted its earnings forecast due to collaboration with Zenas, raising this year's earnings per share to RMB 0.05, lowering next year's to RMB 0.06, and reducing the target price from RMB 25.8 to RMB 23.6, maintaining a "Buy" rating

    AASTOCKS·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%
    AASTOCKS·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%

    The overall performance of companies on the Sci-Tech Innovation Board has regained an upward trend in the first three quarters

    On the evening of November 13th, with the completion of the third quarter report disclosures by two red-chip companies listed in multiple locations, SMIC and InnoCare Pharma, the "report cards" of 592 companies on the STAR Market were all released. In the first three quarters, facing a complex external environment, the overall performance of STAR Market companies rebounded, with a significant year-on-year increase of 75% in net profit for a single quarter. "Hard technology" companies continued to increase their R&D investment, accelerating the cultivation of new productive forces in key industries such as integrated circuits, artificial intelligence, and biomedicine, paving the way for achieving high-level technological self-reliance and strength during the 14th Five-Year Plan period and laying a solid foundation. (Shanghai Securities Journal)

    36Kr·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%
    36Kr·
    SH
    688428
    +0.60%
    HK
    09969
    -0.55%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer